Medicure Inc V.MPH

Alternate Symbol(s): MCUJF

Healthcare Biotechnology

Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company’s United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

TSXV:MPH - Post by User

Medicure Inc

Bullboard Posts

Comment by eSnowdenon May 04, 2018 7:07pm

208 Views

Post# 27985846

RE:RE:RE:May 2nd conference call

Apicore sold for $105 million USD to Mylan labs in the US. After the debt is paid, that leaves nearly $60 million USD. The current valuation of Medicure is $75million USD...so essentially the co. is valued at $15million. I applaud Albert for getting the co. out of bankruptcy, but with declining revenues & questionable growth ahead, I'm a bit worried about future prospects for the co. In addition, published employee reviews concerning MPH are not favorable. I hope this co. can be turned around.

Bullboard Posts

Sparta and Parametric join forces to advance autonomous medicine project